Healthcare
Live Price
Offline$8.58
+0.00% today
1Y Change
-50.44%
Window
Jun 23, 2025 → Jun 11, 2026
Coverage: 244 bars · Jun 23, 2025 → Jun 11, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
PT Kalbe Farma Tbk. (PTKFY) is a Healthcare stock with a market cap of $39.17T and listed on OTC. The stock last traded around $8.58 and down 50.4% across the available one-year price window (Jun 23, 2025 → Jun 11, 2026). Baseline metrics include revenue growth of +8.3%, EPS growth of +15.3%, a dividend yield of 4.2%. What stands out right now is revenue +8.3%, EPS +15.3%, free cash flow -30.4% with operating margin 12.3% and ROIC 13.2%. The dividend matters to the case here, with a current yield around 4.2%. Valuation is more restrained than many high-expectation growth names at P/E 10.8 and price/sales 1.1. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines PTKFY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PTKFY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PTKFY Max Drawdown
-56.02%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PTKFY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$26.3T
-9.2% YoY
FY Net Income
$3.2T
-5.9% YoY
Free Cash Flow
$1.8T
-37.1% YoY
Revenue Growth
+8.3%
EPS Growth
+15.3%
Gross Margin
38.7%
Net Margin
10.0%
Income statement
IDR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 35324.5B | 32627.8B | 30449.1B | 28933.5B | 26261.2B |
| Gross Profit | 14055.5B | 12957.0B | 11823.2B | 11704.1B | 11283.8B |
| Operating Income | 4545.0B | 4067.4B | 3630.8B | 4492.2B | 4160.7B |
| EBITDA | 5179.7B | 4614.0B | 4022.8B | 5246.1B | 4874.5B |
| Net Income | 3665.0B | 3240.6B | 2766.7B | 3382.2B | 3183.6B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
IDR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 4331.4B | 4723.3B | 3232.4B | 3949.8B | 6216.2B |
| Total Assets | 30699.3B | 29429.7B | 27057.6B | 27241.3B | 25666.6B |
| Total Liabilities | 5970.8B | 4839.3B | 3937.5B | 5144.0B | 4400.8B |
| Shareholder Equity | 23312.5B | 22788.9B | 21418.9B | 20385.2B | 19579.5B |
| Total Debt | 297.3B | 559.2B | 618.5B | 1167.7B | 626.2B |
| Net Debt | -4034.2B | -4164.1B | -2613.9B | -2782.1B | -5590.1B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
2825.9B
-25.0% YoY
Capital Expenditures
1000.9B
-15.0% YoY
Free Cash Flow
1825.1B
-37.1% YoY
Key ratios
Gross Margin
38.7%
Operating Margin
12.3%
Net Margin
10.0%
ROE
15.6%
Debt / Equity
0.01x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.